Similar Papers

Paper Title
Journal
Date
Author
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
Shyamala C Navada ... Guillermo Garcia-Manero
Blood | VOL. 126
Shyamala C Navada, et. al.Shyamala C Navada ... Guillermo Garcia-Manero
03 Dec 2015
A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503
Brian A Jonas ... Aaron C Logan
Blood | VOL. 132
Brian A Jonas, et. al.Brian A Jonas ... Aaron C Logan
29 Nov 2018
Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Guillermo Garcia-Manero ... Lewis R Silverman
Blood | VOL. 128
Guillermo Garcia-Manero, et. al.Guillermo Garcia-Manero ... Lewis R Silverman
02 Dec 2016
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
The dark zone of CNS relapse in DLBCL
Kieron Dunleavy
Blood | VOL. 145
Kieron DunleavyKieron Dunleavy
06 Feb 2025
Impact of new medications on the treatment of Immune TTP.
Marie Scully ... William A Lester
Blood | VOL. -
Marie Scully, et. al.Marie Scully ... William A Lester
06 Feb 2025
No exit: targeting RNA export in T-cell malignancy
Katherine L B Borden
Blood | VOL. 145
Katherine L B BordenKatherine L B Borden
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.